Back to Trades
Khan Najat
CEO and PresidentDirectorCIK 0002020969
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 9
- Buy transactions
- 0
- Sell transactions
- 3
- Companies
- 1
- Active
- 2025–2026
Across 9 filings between 2025–2026, Khan Najat, CEO and President, Director, has disclosed $2.3M in transactions — all concentrated in RECURSION PHARMACEUTICALS, INC. (RXRX). Their disclosed trades are heavily weighted toward selling — $0 in buys and $835.2K in sells. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
9 loaded
| Aug 18 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Tax withheld | $254.4K |
| Jun 5 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Sell | $84.5K |
| May 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Tax withheld | $190.6K |
| Feb 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Tax withheld | $49.8K |
| Feb 10 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Grant | $41.2K |
| Dec 29 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Sell | $548.6K |
| Nov 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Tax withheld | $72.8K |
| Nov 6 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Grant | $842.5K |
| Aug 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Sell | $202.2K |
9 filings